Megestrol Acetate in Cachectic Patients with Advanced Bronchogenic Cancer
作者:
M. Heckmayr,
U. Gatzemeier,
期刊:
Onkologie
(Karger Available online 1990)
卷期:
Volume 13,
issue 4
页码: 285-287
ISSN:0378-584X
年代: 1990
DOI:10.1159/000216777
出版商: S. Karger GmbH
关键词: Megestrol acetate;Tumor cachexia;Cachectin;Tumor necrosis factor;Bronchogenic carcinomas
数据来源: Karger
摘要:
Megestrol acetate, a semisynthetic gestagen, is effective not only for endocrine therapy of advanced breast carcinoma, but also in treatment of cachectic patients with aggressive, hormone-independent tumors. 40 patients with therapy-resistent, advanced bronchogenic carcinoma of different histologic type, who had lost more than ten percent of their regular body weight within a prospective, non-randomized trial were treated with megestrol acetate at a dose of either 160 mg/day or 480mg/day for 3–4 months. The average weight gain of all patients was 3.0 kg. Nearly all of them (80%) reported improved appetite and well-being. The weight gain in the group of patients receiving 160 mg/ day was higher (80 %) than in the group receiving 480 mg/day (50 %) suggesting that the lower dose is as effective as the higher one for palliative treatmen
点击下载:
PDF
(1204KB)
返 回